The FDA’s penalties for unapproved drugs run from a written warning all the way to federal prison, and the statutory fine numbers are far smaller than the fines a court can actually impose. Selling a new drug in interstate commerce without an approved application violates 21 U.S.C. § 355(a), and the agency has a graduated set of tools — warning letters, seizure, injunctions, and criminal referral — that it deploys based on how much risk the product poses and whether the company cooperates.
What Triggers Enforcement
Federal law treats a drug as “new” whenever qualified scientific experts do not generally recognize it as safe and effective for its labeled use.1Office of the Law Revision Counsel. 21 USC 321 – Definitions; Generally That definition catches more than novel compounds. A drug that has been sold for decades can still be legally “new,” and therefore unapproved, if no one ever submitted the clinical data to prove it works.
To sell a drug lawfully in the United States, a manufacturer generally needs an approved New Drug Application or an Abbreviated New Drug Application for generics.2U.S. Food and Drug Administration. Abbreviated New Drug Application (ANDA) Without one, the product is unapproved no matter how many providers prescribe it or how long it has been on shelves.3Office of the Law Revision Counsel. 21 USC 355 – New Drugs
Warning Letters
Most enforcement starts with a warning letter. The letter tells the manufacturer that the FDA believes a product violates federal law and asks for a written response, usually within 15 working days.4Food and Drug Administration. Regulatory Procedures Manual – Chapter 4 Advisory Actions The point is to get voluntary compliance before the agency spends resources on litigation.5U.S. Food and Drug Administration. About Warning and Close-Out Letters
A warning letter has no binding force on its own. What it does is establish prior notice, which strengthens the FDA’s position if the case later moves to seizure, injunction, or criminal charges. Ignoring one is the most reliable way to escalate the matter.
Seizure and Administrative Detention
Under 21 U.S.C. § 334, the FDA can move to seize adulterated, misbranded, or unapproved drug products. The government files a complaint in the federal district where the products sit, and U.S. Marshals take custody. Seized products can be condemned and destroyed by court order.6Office of the Law Revision Counsel. 21 USC 334 – Seizure
During an inspection, FDA investigators can also issue an administrative detention order that holds suspect products in place for up to 20 days, extendable to 30, while the agency prepares a formal seizure or seeks an injunction. It’s a short-term freeze designed to keep questionable product from shipping.
Injunctions and Consent Decrees
When the FDA needs a company to stop operating, it can seek an injunction in federal court under 21 U.S.C. § 332.7Office of the Law Revision Counsel. 21 USC 332 – Injunction Proceedings A court can order a manufacturer to halt production and distribution until it proves full compliance. Many cases end in consent decrees, where the company agrees to specific conditions such as stopping all manufacturing until the FDA verifies its operations. Violating an injunction or consent decree adds contempt of court on top, with its own fines and possible jail time.
Criminal Charges and the Real Fine Numbers
The most serious violations go to the Department of Justice for prosecution under 21 U.S.C. § 333. A first offense is a misdemeanor carrying up to one year in prison. A repeat offense, or a violation committed with intent to defraud or mislead, is a felony carrying up to three years.8Office of the Law Revision Counsel. 21 USC 333 – Penalties
The fine amounts written into the statute itself look almost trivial: $1,000 for a first offense and $10,000 for subsequent or fraudulent violations. The real exposure sits somewhere else entirely. Under the federal Alternative Fines Act, a court can impose:
- Up to $100,000 per misdemeanor count against an individual
- Up to $250,000 per felony count against an individual
- Up to $200,000 per misdemeanor count against an organization
- Up to $500,000 per felony count against an organization
- Or, if the violation produced a profit or caused a measurable loss, up to twice the gross gain or twice the gross loss, whichever is greater9Office of the Law Revision Counsel. 18 USC 3571 – Sentence of Fine
That “twice the gross gain” alternative is what turns criminal enforcement into a genuine financial threat rather than a symbolic one. A manufacturer that made tens of millions selling an unapproved product can face a fine calculated from that revenue, not from a fixed statutory cap.
Recalls
Most drug recalls are voluntary. The FDA can also request a recall when it identifies a safety concern, and in some circumstances it has authority to order one.10U.S. Food and Drug Administration. Recalls Background and Definitions For unapproved drugs specifically, the agency more often relies on seizure and injunction. The underlying problem isn’t a defect in an otherwise-legal product — it’s that the product was never authorized to begin with.
How the FDA Decides Who Gets Hit First
Thousands of unapproved drugs are on the market at any given moment, and the FDA follows a risk-based framework in Compliance Policy Guide Section 440.100 to sort them.11U.S. Food and Drug Administration. Unapproved New Drugs Products that get priority attention include:
- Drugs with known safety risks or harmful ingredients
- Drugs lacking any evidence of effectiveness, where reliance on the product can delay real treatment
- Health fraud products with deceptive disease claims, particularly those aimed at people with chronic or terminal conditions
- Unapproved drugs that compete directly with a product that went through the full NDA process, or that violate a final OTC monograph
- Unapproved products that also violate other FD&C Act provisions such as adulteration or misbranding
Recent enforcement has leaned heavily on compounded products. In one recent quarter the FDA’s Center for Drug Evaluation and Research issued more than 50 warning letters and more than 50 untitled letters, with a particular focus on compounded obesity drugs and products falsely implied to be generic versions of approved medications.
Exceptions That Keep a Product Out of Trouble
Not every drug on the market needs an individual NDA, and understanding the exceptions matters because losing one converts a legal product into an enforcement target.
OTC monograph products. Over-the-counter drugs like common antacids and sunscreens can be sold without an NDA if they conform to an FDA monograph covering active ingredients, dosages, labeling, and testing for that therapeutic category. A product that meets every condition is treated as generally recognized as safe and effective under Section 505G.12U.S. Food and Drug Administration. Over-the-Counter (OTC) Drug Review – OTC Monograph Reform in the CARES Act Deviate from the monograph — add an unapproved ingredient, change the dose, or make a claim outside its scope — and the product becomes an unapproved new drug.
Compounded drugs. Section 503A exempts drugs compounded by a licensed pharmacist or physician from the NDA requirement, provided the compounding is based on a valid individual prescription, uses bulk ingredients meeting pharmacopeial standards, and doesn’t produce a commercial copy of an already-available drug.13Food and Drug Administration. Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Interstate shipments are generally capped at 5% of total prescription orders unless the state has a memorandum of understanding with the FDA. Outsourcing facilities operating under Section 503B can compound without individual prescriptions but must register with the FDA, pay annual fees, follow current good manufacturing practice standards, and accept risk-based inspection.14U.S. Food and Drug Administration. Guidance for Industry – Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act A facility that fails to register or ignores CGMP loses the exemption and is treated like any other unapproved-drug manufacturer.
Grandfathered drugs. A drug is not “new” if it was on the market before June 25, 1938 with the same therapeutic claims it carries today, and was also subject to the Food and Drugs Act of 1906.1Office of the Law Revision Counsel. 21 USC 321 – Definitions; Generally The FDA and courts read this exemption very narrowly, and the burden of proof falls entirely on the company claiming it. Any change in composition, dosage form, or labeling claims since 1938 destroys it. This exemption is separate from the Drug Efficacy Study Implementation program, which reviewed drugs approved between 1938 and 1962; a DESI drug is not grandfathered.15U.S. Food and Drug Administration. Drug Efficacy Study Implementation (DESI)
Drug shortages. When patients cannot get medications they need, the FDA may allow a foreign manufacturer to temporarily send unapproved product into the U.S. market after evaluating the formulation and the manufacturing site.16U.S. Food and Drug Administration. Frequently Asked Questions about Drug Shortages This is enforcement discretion, not authorization. The product stays technically unapproved and access can be revoked once domestic supply recovers.
Personal importation. Individuals importing unapproved drugs for their own use are technically violating the FD&C Act. The FDA may exercise discretion when the drug treats a serious condition with no effective domestic treatment, the product does not pose unreasonable risk, the quantity does not exceed a three-month supply, and the person affirms personal use in writing and names a U.S.-licensed physician responsible for their treatment.17U.S. Food and Drug Administration. Personal Importation These conditions describe when the FDA is less likely to intervene, not a legal right to import.
How to Check Whether a Drug Is Actually Approved
A National Drug Code number does not mean a drug is approved. The NDC Directory contains listing data for both approved and unapproved products, and the FDA warns that “any representation that creates an impression of FDA approval because a product has an NDC number is misleading and violates federal law.”18U.S. Food and Drug Administration. National Drug Code Directory
The reliable place to check is the FDA’s Orange Book (formally, Approved Drug Products with Therapeutic Equivalence Evaluations), which lists only drugs approved based on safety and effectiveness and can be searched by active ingredient, brand name, applicant, application number, or dosage form.19U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) The Drugs@FDA database covers most approved prescription, generic, and OTC drugs. If a product doesn’t appear in either, that’s a strong signal it lacks approval, though compounded drugs and OTC monograph products won’t appear there either because they operate under different legal frameworks.